The effect of medical drug reminder mobile application on treatment compliance in women with breast cancer under adjuvant hormone treatment

Öz

Purpose: This study was planned to investigate the effects of a nurse-led medication reminder mobile application on treatment adherence in women with breast cancer receiving adjuvant hormone therapy. Materials and methods: The research was planned as a prospective quasi-experimental study with pretest, posttest, and control groups, in which the simple randomization method was employed. It consisted of 52 women with breast cancer receiving adjuvant hormone therapy, including 26 in the experimental group and 26 in the control group. The medication reminder mobile application developed by the researchers was utilized in the experimental group to determine its effect on treatment adherence. Data collection measures included a personal information form and the Medication Adherence Self-Efficacy Scale (MASES). After the baseline data of the experimental and control groups were collected, the experimental group used the “Medication Reminder” mobile application for eight weeks. At the end of the eight weeks, the MASES was applied to both groups again. Results: A statistically significant difference was found between the pre-test and post-test MASES total scores of the experimental group (p<0.05). The post-test MASES total scores of the experimental group were significantly higher than their pre-test scores. The inter-group comparisons indicated that the post-test MASES total scores of the experimental group were statistically significantly higher than those of the control group (p<0.05). Conclusion: It was concluded that the “Medication Reminder” mobile application was an effective tool in increasing treatment adherence in women with breast cancer under adjuvant hormone therapy.

Anahtar Kelimeler

• Adjuvant hormone therapy
• breast cancer
• medication adherence
• mobile application
• women

Adjuvan hormon tedavisi gören meme kanserli kadınlarda, ilaç hatırlatma mobil uygulamasının tedaviye uyum üzerine etkisi

Öz

Amaç: Bu araştırma, adjuvan hormon tedavisi almakta olan meme kanseri kadınlarda, hemşire öncülüğünde hazırlanmış ilaç hatırlatma mobil uygulamasının tedaviye uyum üzerine etkisinin incelenmesi amacıyla planlanmıştır. Gereç ve yöntemler: Bu araştırma ön test-son test kontrol gruplu, prospektif, basit randomizasyon yöntemi kullanılan, yarı deneysel bir çalışma olarak planlanmış olup, 26 deney ve 26 kontrol grubu olmak üzere toplam 52 adjuvan hormon tedavisi gören meme kanserli kadın ile yürütülmüştür. Araştırmacılar tarafından geliştirilen ilaç alarmı mobil uygulaması deney grubuna tedaviye uyum üzerine etkisini belirlemek amacıyla uygulanmıştır. Verilerin toplanmasında Kişisel Bilgi Formu ve İlaç Tedavisine Bağlılık/Uyum Öz-Etkililik Ölçeği (MASES) kullanılmıştır. Deney ve kontrol grubunun ilk verilerinin toplanmasının ardından deney grubu 8 hafta süre ile “İlaç Alarmı” mobil uygulamasını kullanmıştır. 8 haftalık sürecin sonunda her iki gruba tekrar MASES uygulanmıştır. Bulgular: Deney grubundakilerin ön test – son test MASES toplam puanları arasında istatistiksel olarak anlamlı farklılık saptanmıştır (p<0,05). Deney grubunun son test MASES toplam puanları ön teste göre anlamlı derecede daha yüksek olduğu tespit edilmiştir. Gruplar arasında ise son test MASES toplam puanları açısından deney grubunun son test toplam puanları istatistiksel olarak anlamlı derece yüksek olduğu saptanmıştır (p<0,05). Sonuç: Adjuvan hormon tedavisi alan meme kanserli hastalarda “İlaç Alarmı” mobil uygulamasının tedaviye uyumu arttırma konusunda etkili bir araç olduğu sonucuna ulaşılmıştır.

Anahtar Kelimeler

• Adjuvan hormon tedavisi
• ilaç uyumu
• meme kanseri
• mobil uygulama
• kadın

Kaynakça

1. 1. Kılıç D, Alataş E. Jinekolojik kanserlerde tarama ve erken tanı-1, Jinekolojik Onkolojide Bakım (ED: Özkan S, Serçekuş P, Alataş E.). Akademisyen Kitapevi, 2022:37-49.
2. 2. Global Cancer Observatory. International Agency for Research on Cancer. Available at:https://gco.iarc.fr/today/online-analysis pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=2&cancer=39&type=2&statistic=5&prevalence=1&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0. Accessed March 11, 2022
3. 3. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31-42. doi:10.3322/caac.21320
4. 4. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518. doi:10.1200/JCO.2009.23.1274
5. 5. Yalçıntaş Arslan Y. Erken evre hormon reseptör pozitif meme kanseri hastada endokrin tedavi seçenekleri; ne kadar süre yeterli? Turkiye Klinikleri J Med Oncol-Special Topics. 2018;11(1):41-46.
6. 6. Brett J, Fenlon D, Boulton M, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.Eur J Cancer Care (Engl). 2018;27(1):10.1111/ecc.12601. doi:10.1111/ecc.12601
7. 7. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763-1768. doi:10.1038/sj.bjc.6604758
8. 8. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120-4128. doi:10.1200/JCO.2009.25.9655

9. 9. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30(9):936-942. doi:10.1200/JCO.2011.38.0261
10. 10. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459-478. doi:10.1007/s10549-012-2114-5
11. 11. Demir Yıldırım A, Yılmaz Esencan T, Güder A, Daştan K. Ebelik alanında kullanılan mobil sağlık uygulamaları. Karya J Health Sci. 2023;4(2):174-178. doi:10.52831/kjhs.1177753
12. 12. Santo K, Richtering SS, Chalmers J, Thiagalingam A, Chow CK, Redfern J. Mobile Phone Apps to Improve Medication Adherence: A Systematic Stepwise Process to Identify High-Quality Apps. JMIR MhealthUhealth. 2016;4(4):e132. Published 2016 Dec 2. doi:10.2196/mhealth.6742
13. 13. Thakkar J, Kurup R, Laba TL, et al. Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis. JAMA Intern Med. 2016;176(3):340-349. doi:10.1001/jamainternmed.2015.7667
14. 14. Barton AJ. The regulation of mobile health applications. BMC Med.2012;10:46. Published 2012 May 8. doi:10.1186/1741-7015-10-46
15. 15. Kagen S, Garland A. Asthma and Allergy Mobile Apps in 2018. Curr Allergy Asthma Rep. 2019;19(1):6. Published 2019 Feb 2. doi:10.1007/s11882-019-0840-z
16. 16. Odeh B, Kayyali R, Nabhani-Gebara S, Philip N. Optimizing cancer care through mobile health. Support Care Cancer. 2015;23(7):2183-2188. doi:10.1007/s00520-015-2627-7
17. 17. Cruz FOAM, Vilela RA, Ferreira EB, Melo NS, Reis PEDD. Evidence on the Use of Mobile Apps During the Treatment of Breast Cancer: Systematic Review. JMIR MhealthUhealth. 2019;7(8):e13245. Published 2019 Aug 27. doi:10.2196/13245
18. 18. Ali EE, Leow JL, Chew L, Yap KY. Patients' Perception of App-based Educational and Behavioural Interventions for Enhancing Oral Anticancer Medication Adherence. J Cancer Educ. 2018;33(6):1306-1313. doi:10.1007/s13187-017-1248-x
19. 19. Çakmak HS. Oral kemoterapiilaçkullanankanserhastalarındamotivasyonelgörüşmetemellidanışmanlığınilaçuyumuveöz-etkililiğeetkisi. DoktoraTezi, HacettepeÜniversitesi, SağlıkBilimleriEnstitüsü, HemşirelikDoktoraProgramı, Ankara, 2018.
20. 20. Graetz I, McKillop CN, Stepanski E, Vidal GA, Anderson JN, Schwartzberg LS. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial. J Cancer Surviv. 2018;12(4):431-440. doi:10.1007/s11764-018-0682-z
21. 21. Krok Schoen JL, Naughton MJ, Young GS, et al. IncreasingAdherencetoAdjuvantHormoneTherapyAmongPatientsWithBreastCancer: A Smart Phone App-Based Pilot Study. Cancer Control. 2019;26(1):1073274819883287. doi:10.1177/1073274819883287
22. 22. Eşer AK. Kanser tedavisinde oral antikanserilaçkullananhastalariçingeliştirilenmobiluygulamanınilaçuyumuvesemptomlarüzerineetkisi. DoktoraTezi, Gazi ÜniversitesiSağlıkBilimleriEnstitüsü, HemşirelikDoktoraProgramı, Ankara, 2020.
23. 23. Gozum S, Hacihasanoglu R. Reliability and validity of the Turkish adaptation of medication adherence self-efficacy scale in hypertensive patients. Eur J Cardiovasc Nurs. 2009;8(2):129-136. doi:10.1016/j.ejcnurse.2008.10.006
24. 24. Tokdemir GY. Kanser tedavisinde oral ajankullananhastalaraverileneğitiminilaçuyumuveöz-etkililiğeetkisi. Yüksek LisansTezi, BaşkentÜniversitesiSağlıkBilimleriEnstitüsü, Doğum- KadınHastalıklarıHemşireliği YL Programı, Ankara, 2011.
25. 25. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42(14):2271-2276. doi:10.1016/j.ejca.2006.03.004
26. 26. Wouters H, Stiggelbout AM, Bouvy ML, et al. Endocrine therapy for breast cancer: assessing an array of women's treatment experiences and perceptions, their perceived self-efficacy and nonadherence. Clin Breast Cancer. 2014;14(6):460-467.e2. doi:10.1016/j.clbc.2014.04.005
27. 27. Haase J, Farris KB, Dorsch MP. Mobile Applications to Improve Medication Adherence. Telemed J E Health. 2017;23(2):75-79. doi:10.1089/tmj.2015.0227
28. 28. Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Understanding tamoxifen adherence in women with breast cancer: A qualitative study. Br J Health Psychol. 2017;22(4):978-997. doi:10.1111/bjhp.12266
29. 29. Brett J, Boulton M, Fenlon D, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence.2018;12:291-300. Published 2018 Feb 16. doi:10.2147/PPA.S145784
30. 30. Clancy C, Lynch J, OConnor P, Dowling M. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis. Eur J Oncol Nurs.2020;44:101706. doi:10.1016/j.ejon.2019.101706
31. 31. Martino G, Catalano A, Agostino RM, et al. Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer. PLoS One. 2020;15(3):e0230681. Published 2020 Mar 26. doi:10.1371/journal.pone.0230681
32. 32. Green SMC, French DP, Graham CD, et al. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy. BMC Health Serv Res. 2022;22(1):1081. Published 2022 Aug 24. doi:10.1186/s12913-022-08243-4
33. 33. Tan EH, Wong ALA, Tan CC, et al. Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder. Breast.2020;53:77-84. doi:10.1016/j.breast.2020.06.012
34. 34. Hershman DL, Unger JM, Hillyer GC, et al. Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. J Clin Oncol. 2020;38(19):2122-2129. doi:10.1200/JCO.19.02699